[go: up one dir, main page]

SI3411358T1 - Substituirana piperidinska spojina in njena uporaba - Google Patents

Substituirana piperidinska spojina in njena uporaba

Info

Publication number
SI3411358T1
SI3411358T1 SI201731054T SI201731054T SI3411358T1 SI 3411358 T1 SI3411358 T1 SI 3411358T1 SI 201731054 T SI201731054 T SI 201731054T SI 201731054 T SI201731054 T SI 201731054T SI 3411358 T1 SI3411358 T1 SI 3411358T1
Authority
SI
Slovenia
Prior art keywords
piperidine compound
substituted piperidine
substituted
compound
piperidine
Prior art date
Application number
SI201731054T
Other languages
English (en)
Inventor
Tatsuhiko Fujimoto
Kentaro Rikimaru
Koichiro Fukuda
Hiromichi Sugimoto
Takahiro Matsumoto
Norihito Tokunaga
Mariko HIROZANE
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of SI3411358T1 publication Critical patent/SI3411358T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201731054T 2016-02-04 2017-02-01 Substituirana piperidinska spojina in njena uporaba SI3411358T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016019834 2016-02-04
EP17705706.4A EP3411358B1 (en) 2016-02-04 2017-02-01 Substituted piperidine compound and use thereof
PCT/JP2017/003610 WO2017135306A1 (en) 2016-02-04 2017-02-01 Substituted piperidine compound and use thereof

Publications (1)

Publication Number Publication Date
SI3411358T1 true SI3411358T1 (sl) 2022-04-29

Family

ID=58054473

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201731054T SI3411358T1 (sl) 2016-02-04 2017-02-01 Substituirana piperidinska spojina in njena uporaba
SI201731551T SI3984994T1 (sl) 2016-02-04 2017-02-01 Substituirana piperidinska spojina kot agonist oreksina tipa 2 za zdravljenje narkolepsije

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201731551T SI3984994T1 (sl) 2016-02-04 2017-02-01 Substituirana piperidinska spojina kot agonist oreksina tipa 2 za zdravljenje narkolepsije

Country Status (36)

Country Link
US (7) US10287305B2 (sl)
EP (3) EP4438041A3 (sl)
JP (1) JP6609060B2 (sl)
KR (1) KR102734774B1 (sl)
CN (2) CN108884043B (sl)
AR (1) AR107519A1 (sl)
AU (1) AU2017215021B2 (sl)
BR (1) BR112018015574B1 (sl)
CA (1) CA3013428C (sl)
CL (1) CL2018002099A1 (sl)
CO (1) CO2018008705A2 (sl)
CY (1) CY1125003T1 (sl)
DK (2) DK3411358T3 (sl)
EA (1) EA036166B1 (sl)
EC (1) ECSP18066504A (sl)
ES (2) ES2907373T3 (sl)
FI (1) FI3984994T3 (sl)
HR (2) HRP20241334T1 (sl)
HU (2) HUE068362T2 (sl)
IL (1) IL260835B (sl)
LT (2) LT3984994T (sl)
MA (1) MA43963A (sl)
MX (1) MX382435B (sl)
MY (1) MY186905A (sl)
PH (1) PH12018501666B1 (sl)
PL (2) PL3984994T3 (sl)
PT (2) PT3984994T (sl)
RS (2) RS65984B1 (sl)
SG (1) SG11201806429PA (sl)
SI (2) SI3411358T1 (sl)
TN (1) TN2018000262A1 (sl)
TW (2) TWI755374B (sl)
UA (1) UA122433C2 (sl)
UY (1) UY37103A (sl)
WO (1) WO2017135306A1 (sl)
ZA (1) ZA201805544B (sl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
PL3984994T3 (pl) * 2016-02-04 2024-11-04 Takeda Pharmaceutical Company Limited Podstawiony związek piperydyny jako agonista oreksyny typu 2 do leczenia narkolepsji
EP3594202B1 (en) 2017-03-08 2021-08-11 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
US11059780B2 (en) 2017-03-08 2021-07-13 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
MY202221A (en) 2017-08-03 2024-04-17 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
JP7189140B2 (ja) * 2017-08-03 2022-12-13 武田薬品工業株式会社 複素環化合物およびその用途
US11673867B2 (en) 2017-12-12 2023-06-13 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
EA039459B1 (ru) * 2017-12-25 2022-01-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа
EP3816153B1 (en) * 2018-06-29 2023-10-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
WO2020122093A1 (ja) 2018-12-12 2020-06-18 武田薬品工業株式会社 複素環化合物
WO2020122092A1 (ja) 2018-12-12 2020-06-18 武田薬品工業株式会社 複素環化合物
US11028048B2 (en) * 2019-01-31 2021-06-08 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3924058B1 (en) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy
CN114555083A (zh) * 2019-09-13 2022-05-27 武田药品工业株式会社 食欲素2受体激动剂用于治疗过度嗜睡的用途
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
PE20221730A1 (es) * 2019-11-27 2022-11-07 Sumitomo Pharma Co Ltd Derivado de cicloalquilurea
WO2021106975A1 (ja) * 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
CN115226390A (zh) * 2020-01-10 2022-10-21 武田药品工业株式会社 使用细胞色素p450的抑制剂增强3-((甲基磺酰基)氨基)-2-(((4-苯基环己基)氧基)甲基)哌啶-1-羧酸甲酯或其盐的药代动力学或增加其血浆浓度的方法
US12497362B2 (en) 2020-08-18 2025-12-16 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
EP4200295A1 (en) 2020-08-18 2023-06-28 Merck Sharp & Dohme LLC Bicycloheptane pyrrolidine orexin receptor agonists
TW202227397A (zh) 2020-09-03 2022-07-16 英商歐瑞夏治療公司 雙環的－雜環衍生物及相關用途
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
EP4247801A4 (en) * 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
TW202302100A (zh) 2021-03-12 2023-01-16 日商武田藥品工業股份有限公司 食慾激素２受體促效劑於治療食慾激素介導之疾病或病症之用途
CA3215906A1 (en) 2021-04-02 2022-10-06 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for post operation recovery
EP4329877B1 (en) * 2021-04-26 2026-02-04 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
MX2023012971A (es) * 2021-05-03 2024-01-16 Jazz Pharmaceuticals Ireland Ltd Agonistas del receptor de orexina y sus usos.
CA3219506A1 (en) * 2021-05-26 2022-12-01 Hoan Huynh Substituted fused bicyclic macrocyclic compounds and related methods of treatment
CA3219490A1 (en) 2021-05-26 2022-12-01 Alkermes, Inc. Substituted carbamate macrocyclic compounds and related methods of treatment
JP7668768B2 (ja) * 2021-05-26 2025-04-25 住友ファーマ株式会社 シクロアルキルウレア誘導体を含有する医薬組成物
US20240308960A1 (en) 2021-05-26 2024-09-19 Sumitomo Pharma Co., Ltd. Phenyl urea derivative
US20250250230A1 (en) * 2022-04-12 2025-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP4512807A1 (en) 2022-04-22 2025-02-26 Sumitomo Pharma Co., Ltd. Bicycloamine carboxamide derivative
CA3260225A1 (en) * 2022-06-21 2023-12-28 Alkermes, Inc. Fused, Substituted Bicyclic Compounds and Associated Treatment Methods
WO2023249872A1 (en) * 2022-06-21 2023-12-28 Alkermes, Inc. Substituted fused bicyclic compounds and related methods of treatment
WO2023249871A1 (en) * 2022-06-21 2023-12-28 Alkermes, Inc. Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment
JPWO2024075825A1 (sl) 2022-10-07 2024-04-11
AU2023375094A1 (en) 2022-10-31 2025-05-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2024095158A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
AU2023403030A1 (en) 2022-11-30 2025-06-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP4635944A1 (en) 2022-12-16 2025-10-22 Daiichi Sankyo Company, Limited 2-azabicyclo[3.1.1]heptane compound
WO2024189597A1 (en) 2023-03-16 2024-09-19 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
WO2024246867A1 (en) 2023-06-02 2024-12-05 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2025211416A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド大環状化合物
WO2025211415A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド化合物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025229492A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Orexin type 2 receptor agonist microcapsules for sustained release dosing
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608602A1 (fr) 1986-12-23 1988-06-24 Cerm Cent Europ Rech Mauvernay Nouvelles 3-piperidineamines ou 3-azepineamines substituees, leur preparation et leurs applications en therapeutique
SE9003652D0 (sv) 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
PT888353E (pt) 1996-03-15 2003-11-28 Novartis Ag Novas n-7-heterociclil-pirrolo¬2,3-d|pirimidinas e sua aplicacao
ES2245003T3 (es) 1996-08-27 2005-12-16 Praecis Pharmaceuticals Incorporated Moduladores de la agregacion de peptidos beta-amiloides que comprenden d-aminoacidos.
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
ATE482233T1 (de) 1999-06-28 2010-10-15 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
WO2001008720A2 (en) 1999-07-30 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Hypocretin and hypocretin receptors in regulation of sleep and related disorders
AU2001251306A1 (en) 2000-04-04 2001-10-15 Siegel, Jerome M. Treatment of sleep disorders with hypocretin-1
CA2498264A1 (en) 2002-09-09 2004-05-13 Nura, Inc. G protein coupled receptors and uses thereof
CA2509215A1 (en) 2002-12-13 2004-07-01 Janssen Pharmaceutica N.V. Method for identifying modulators of human orexin-2 receptor
CN101679366B (zh) * 2007-05-23 2013-08-07 默沙东公司 吡啶基哌啶食欲素受体拮抗剂
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
JP2013523642A (ja) 2010-03-26 2013-06-17 メルク・シャープ・エンド・ドーム・コーポレイション グルカゴン受容体拮抗薬としての新規なスピロイミダゾロン誘導体、組成物およびそれらの使用方法
US9527807B2 (en) * 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
US20140296288A1 (en) 2011-07-20 2014-10-02 Universite Pierre Et Marie Curie (Paris 6) Imino-sugar c-glycosides, preparation and use thereof
JP6484553B2 (ja) * 2012-07-03 2019-03-13 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ オレキシン受容体アンタゴニスト
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
JP6440321B2 (ja) 2013-12-12 2018-12-19 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2015131773A1 (zh) 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
EP3029024A1 (en) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
JP6746107B2 (ja) 2015-02-19 2020-08-26 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
JP6189905B2 (ja) 2015-09-30 2017-08-30 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、及びビデオゲーム処理システム
PL3984994T3 (pl) 2016-02-04 2024-11-04 Takeda Pharmaceutical Company Limited Podstawiony związek piperydyny jako agonista oreksyny typu 2 do leczenia narkolepsji

Also Published As

Publication number Publication date
CN108884043B (zh) 2021-11-26
US11292766B2 (en) 2022-04-05
HUE068362T2 (hu) 2024-12-28
US20260001843A1 (en) 2026-01-01
HUE057696T2 (hu) 2022-05-28
US20190263843A1 (en) 2019-08-29
PT3411358T (pt) 2022-01-19
MA43963A (fr) 2018-12-12
RS62861B1 (sr) 2022-02-28
PH12018501666B1 (en) 2023-05-26
EP3411358B1 (en) 2021-11-24
BR112018015574A2 (pt) 2018-12-26
UA122433C2 (uk) 2020-11-10
US20240174610A1 (en) 2024-05-30
RS65984B1 (sr) 2024-10-31
EP3984994B1 (en) 2024-07-03
MX2018009494A (es) 2018-09-06
JP2019504098A (ja) 2019-02-14
CN114181136A (zh) 2022-03-15
CA3013428C (en) 2024-02-13
CO2018008705A2 (es) 2018-11-13
CN108884043A (zh) 2018-11-23
AR107519A1 (es) 2018-05-09
EP3984994A1 (en) 2022-04-20
US20220081399A1 (en) 2022-03-17
TW202220959A (zh) 2022-06-01
US20200115399A1 (en) 2020-04-16
BR112018015574B1 (pt) 2023-11-28
IL260835A (en) 2019-02-28
KR20180103985A (ko) 2018-09-19
JP6609060B2 (ja) 2019-11-20
CA3013428A1 (en) 2017-08-10
KR102734774B1 (ko) 2024-11-26
EP4438041A3 (en) 2025-01-01
NZ745259A (en) 2025-03-28
EA201891742A1 (ru) 2019-01-31
CY1125003T1 (el) 2023-01-05
DK3984994T3 (da) 2024-10-14
MY186905A (en) 2021-08-26
US20190031611A1 (en) 2019-01-31
HRP20241334T1 (hr) 2025-01-03
IL260835B (en) 2021-10-31
LT3984994T (lt) 2024-10-10
EP4438041A2 (en) 2024-10-02
US10508083B2 (en) 2019-12-17
SG11201806429PA (en) 2018-08-30
ECSP18066504A (es) 2018-10-31
LT3411358T (lt) 2022-04-25
HRP20220127T1 (hr) 2022-04-15
EP3411358A1 (en) 2018-12-12
TN2018000262A1 (en) 2020-01-16
AU2017215021A1 (en) 2018-08-30
TW201731817A (zh) 2017-09-16
ES2907373T3 (es) 2022-04-25
PL3984994T3 (pl) 2024-11-04
PT3984994T (pt) 2024-10-10
WO2017135306A1 (en) 2017-08-10
US10898737B2 (en) 2021-01-26
ZA201805544B (en) 2019-11-27
DK3411358T3 (da) 2022-01-17
SI3984994T1 (sl) 2024-12-31
PL3411358T3 (pl) 2022-02-28
PH12018501666A1 (en) 2019-06-17
FI3984994T3 (fi) 2024-10-03
AU2017215021B2 (en) 2020-07-23
EA036166B1 (ru) 2020-10-08
CL2018002099A1 (es) 2018-11-09
MX382435B (es) 2025-03-13
US20170226137A1 (en) 2017-08-10
ES2991028T3 (es) 2024-12-02
US10287305B2 (en) 2019-05-14
TWI755374B (zh) 2022-02-21
UY37103A (es) 2017-08-31
US12281073B2 (en) 2025-04-22

Similar Documents

Publication Publication Date Title
ZA201805544B (en) Substituted piperidine compound and use thereof
IL273236A (en) Pyrazolopyrimidine compounds and their uses
IL258180B (en) Heterocyclic compounds and their uses
SG11201706029VA (en) Anti-senescence compounds and uses thereof
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201608779D0 (en) Methods and compounds
GB201616439D0 (en) Compounds and uses
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
GB201608776D0 (en) Methods and compounds
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
IL253459A0 (en) Isoergoline compounds and their uses
GB201700404D0 (en) Compounds and composistions
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
PT3263133T (pt) Composto de piridinona e a sua utilização
GB201614224D0 (en) Compounds and uses thereof
IL265617B (en) 1-phenylpropanone compounds and their use
HK1260284A1 (en) Substituted piperidine compound and use thereof
GB201719043D0 (en) Methods and compounds
GB201602572D0 (en) New compound and uses
GB201614874D0 (en) New compounds and uses
GB201613134D0 (en) Novel compounds and their use
HUE050178T2 (hu) Piridinon vegyület és alkalmazása